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to differentiate into an antibody-secreting
cell or return to the dark zone? In addition
to providing a platform for addressing
these questions, the powerful application
of photoactivatable-GFP in this study
should spur broader use of this tech-
nology to relate cell location with gene
expression and cell fate.ACKNOWLEDGMENTS
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Perception of pain involves both the peripheral and central nervous systems. Starting with a whole-
genomeRNA interference screen inDrosophila, Neely et al. (2010) identify amammalian gene that is
required not only for efficient transfer of pain signals between brain centers, but also for the
suppression of inappropriate signaling between other sensory systems.Even though humanity’s attempts to
control pain can be traced back through
the millennia, much of our current arsenal
of therapies still has its roots in folk
remedies. Originally derived from natural
plant products such as willow bark and
poppies, these medicines have been the
mainstay of chronic pain control for
many years. Unfortunately, even modern
therapies for chronic pain are too often
ineffective, leaving untold numbers of indi-
viduals suffering worldwide. As we move
into the postgenomic era, hopes have
been raised that the problem of pain will
be solved, largely by getting to grips with
the underlying genetic, molecular, and
cellular mechanisms involved in nocicep-
tion. It is also expected that interindividual
variability in pain experience, a major
issue confounding effective treatment,
will be accounted for in some part by vari-
ations in a definable subset of genes.
The report by Neely et al. (2010) in this
issue of Cell represents a major advancein the search for the genes and mecha-
nisms of pain and variability in its
perception. In an impressively multifac-
eted study that extends from fruit flies to
mice and ultimately to humans, the
authors have uncovered a new molecular
player, a2d3, in pain. Along the way, they
also made some highly unexpected
observations indicating that a2d3 is not
only involved in pain, but also plays
a role in the poorly understood mecha-
nisms that separate one form of sensory
information from another.
The fruit fly provides an ideal model
for unraveling genetic aspects of human
disease, with advantages including a
short generation time and the capacity
to analyze extremely large numbers of
animals in a high-throughput manner.
Genome-wide RNA interference (RNAi)
screens are a powerful investigative tool
given the fly’s relatively small (15,000
genes) but extremely well-annotated
genome and sufficient homology withthe human genome to permit the identifi-
cation of conserved pathways in flies
and humans.
In a Herculean undertaking, Neely et al.
take advantage of the Vienna global
Drosophila RNAi library (Dietzl et al.,
2007) to individually knock down almost
every gene in the fly genome, specifically
in neural tissues. Each line was then
painstakingly tested using a behavioral
assay to measure sensitivity to noxious
heat. In total, 580 genes are identified
that potentially regulate thermal nocicep-
tion and possibly basic neuronal function.
One of the genes identified is straight-
jacket, which is one of several a2d genes
that encode calcium channel subunits.
Themammalian homolog of straightjacket
is CACNAD2D3, which encodes the a2d3
subunit. Of interest, a close relative of this
protein, a2d1, is the molecular target for
the analgesics gabapentin and pregabalin
(Field et al., 2006). To further investigate
the function of a2d3, the authorsovember 12, 2010 ª2010 Elsevier Inc. 505
Figure 1. Sounds, Sights, and Smells of Pain
In the mouse brain, nociceptive signals are relayed from the thalamus to the
somatosensory and motor regions of the cortex. Visualized by functional
magnetic resonance imaging (fMRI), mice lacking the gene encoding a2d3
display a significant reduction in activation of these regions, consistent with
reduced perception of a painful thermal stimulus. Surprisingly, however, other
regions of the cortex, including those involved in olfaction, vision, and hearing,
are activated by the same stimulus.generated a knockout
mouse. Intriguingly, its
expression in the mouse is
entirely restricted to the brain,
being completely absent from
the spinal cord and dorsal
root ganglia. This suggests
that, unlike the function of
Straightjacket in flies,
mammalian a2d3 likely medi-
ates the last leg of the noci-
ceptive relay, the transmis-
sion of the signal from the
thalamus up to the highest
level, the cortex.
To test the relevance of
their findings in humans,
Neely et al. identify and
screen four single-nucleotide
polymorphisms (SNPs) in the
human CACNA2D3 gene.
One of these, rs6777055, is
significantly associated with
reduced thermal sensitivity.
In these experiments, the
volunteers are given a series
of short pulses of painful heat.Although the temperature of the pulses
remains the same, most people tend to
perceive the stimulus as becoming
progressively more painful. In a small
number of subjects, however, this does
not occur, and it is these individuals that
are found to express the rs6777055 minor
allele of the CACNA2D3 gene.
Surprising similarities emerge between
the a2d3 knockout mouse and humans
with SNPs that interfere with a2d3 func-
tion. For both, it appears that acute pain
sensitivity is reduced (although spinal
reflex-mediated events such as tail flick
remain normal, in line with the absence
of a2d3 expression in peripheral and
spinal sensory circuitry in the mouse).
Furthermore, both thermal hypersensi-
tivity following inflammation in mice and
perception of chronic back pain in
humans appear to involve a2d3; patients
expressing the rs6777055 SNP report
reduced pain 1 year after corrective
surgery compared to non-SNP patients.
In addition to the remarkable insight
into pain processing that these studies
reveal, a fascinating and unexpected
phenomenon emerges from their studies
using functional magnetic resonance
imaging (fMRI) of the a2d3-deficient
mice. Noxious thermal stimulation nor-506 Cell 143, November 12, 2010 ª2010 Elsemally activates a characteristic set of
brain structures associated with pain per-
ception. Known as the pain matrix, this
center includes the thalamus and somato-
sensory cortex. In the a2d3 mutant
mouse, activation of the pain matrix is
markedly diminished, with the fMRI signal
seemingly unable to spread from the thal-
amus to higher cortical regions. There-
fore, it appears that, in mammals, a2d3
is necessary not for the detection of
noxious heat but for the transmission of
thermal nociceptive signals to higher
areas of the central nervous system, in
particular those associated with the pro-
cessing of pain signals.
However, this is not the only finding of
the fMRI study. When looking at total acti-
vation in the brain, the authors find no
difference between control and a2d3-
deficient mice. This at first seems coun-
terintuitive, given the large reduction in
fMRI signal from thalamocortical projec-
tions in the mutant mouse. Upon closer
investigation, it becomes evident that
other entirely unrelated brain regions are
instead being activated, including visual,
auditory, and olfactory regions (Figure 1).
Even more remarkably, when another
sensory modality, tactile stimulation of
the vibrissae, is tested, not only does thevier Inc.MRI signal in the
primary cortical area (the
barrel fields of the somato-
sensory cortex) remain
unchanged in mutant
compared to wild-type mice,
but cross-activation to other
sensory brain regions is also
observed. It therefore
appears that mice lacking
a2d3 develop a form of
synesthesia, a condition
whereby stimulation of one
sensory pathway elicits
perception in one or more
other sensory modalities.
Although transmission of
thermal nociception is dimin-
ished, other sensory systems
tested, such as touch, remain
unaffected.
The study by Neely et al.
offers a compelling insight
into nociceptive transmission
in higher areas of the central
nervous system. In doing so,
it also raises many questionsfor future investigation. On a molecular
level, a2d3 is known to regulate calcium
channel expression and its targeting to
presynaptic sites (Dolphin, 2009). A
recent report suggests that a2d3 can be
GPI anchored to the membrane and that
this modification is necessary for a2d3-
mediated enhancement of calcium
currents (Davies et al., 2010; Bauer
et al., 2010). Evidence is also now
emerging that, in Drosophila, a2d3 is
required for synaptic morphogenesis
(Kurshan et al., 2009). Of interest, how-
ever, this function appears to be indepen-
dent of its role in regulating voltage-
gated calcium channels. In light of
this multifunctionality, the question arises
as to what exactly is deficient in the
a2d3-deficient mice. In particular, the
synaptic consequences of eliminating
a2d3 throughout mouse development
remain unknown.
Given the close relationship between
a2d3 and a2d1, it would also be of great
interest to test what happens to a2d3
expression after peripheral nerve injury,
as a2d1 is upregulated in the somatosen-
sory system after nerve injury, concurrent
with the onset of behavioral pain hyper-
sensitivity. Furthermore, although the
human studies presented indicate that
chronic pain states may indeed be medi-
ated by the action of a2d3, it remains to
be seen whether this can be modeled in
mice. Finally, the cross-sensory activation
in a2d3-deficient mice raises the question
as to whether synesthesia in humans is in
any way related to a2d3 polymorphisms.
Despite considerable research and
major mechanistic breakthroughs in
recent years, pain remains the most
common cause of disability and impaired
quality of life and, as such, represents
an enormous socioeconomic problem.
The identification of a2d3 as a player in
the mechanisms of pain and a molecule
accounting for a portion of interindividualpain variability opens up new possibilities
for rationally designed and individualized
pain therapies. The biggest challenge
now is to find safe and effective ways to
use this discovery to truly put a straight-
jacket on pain.REFERENCES
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